Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
When should prophylaxis therapy in inhibitor patients be considered?
Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. Young G, et al. Among authors: blanchette v. Haemophilia. 2011 Sep;17(5):e849-57. doi: 10.1111/j.1365-2516.2011.02494.x. Epub 2011 Mar 21. Haemophilia. 2011. PMID: 21418444 Review.
Defining extended half-life rFVIII-A critical review of the evidence.
Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Mahlangu J, et al. Among authors: blanchette v. Haemophilia. 2018 May;24(3):348-358. doi: 10.1111/hae.13438. Epub 2018 Apr 6. Haemophilia. 2018. PMID: 29633467 Review.
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Iorio A, et al. Among authors: blanchette v. Haemophilia. 2017 May;23(3):e170-e179. doi: 10.1111/hae.13215. Epub 2017 Mar 26. Haemophilia. 2017. PMID: 28345268
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C. Valentino LA, et al. Among authors: blanchette v. Haemophilia. 2009 Jul;15(4):959-65. doi: 10.1111/j.1365-2516.2008.01953.x. Epub 2009 Mar 23. Haemophilia. 2009. PMID: 19320750 No abstract available.
Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.
Fischer K, Poonnoose P, Dunn AL, Babyn P, Manco-Johnson MJ, David JA, van der Net J, Feldman B, Berger K, Carcao M, de Kleijn P, Silva M, Hilliard P, Doria A, Srivastava A, Blanchette V; participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy. Fischer K, et al. Among authors: blanchette v. Haemophilia. 2017 Jan;23(1):11-24. doi: 10.1111/hae.13088. Epub 2016 Sep 15. Haemophilia. 2017. PMID: 27633342 Review.
Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
Carcao M, Zunino L, Young NL, Dover S, Bouskill V, Hilliard P, Price VE, Blanchette VS. Carcao M, et al. Among authors: blanchette vs. Haemophilia. 2020 Jan;26(1):73-78. doi: 10.1111/hae.13905. Epub 2019 Dec 22. Haemophilia. 2020. PMID: 31865620
Patterns of joint damage in severe haemophilia A treated with prophylaxis.
Goren R, Pullenayegum E, Blanchette VS, Dover S, Carcao M, Israels SJ, Chan A, Rivard GE, Steele M, Cloutier S, Klaassen RJ, Sinha R, Price VE, Laferriere N, Paradis E, Wu JK, Feldman BM. Goren R, et al. Haemophilia. 2021 Jul;27(4):666-673. doi: 10.1111/hae.14345. Epub 2021 May 20. Haemophilia. 2021. PMID: 34015166
402 results